# Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

> **NCT06461299** · PHASE4 · COMPLETED · sponsor: **The Dermatology Institute of Boston** · enrollment: 9 (actual)

## Conditions studied

- Perioral Dermatitis

## Interventions

- **DRUG:** Seysara Oral Product

## Key facts

- **NCT ID:** NCT06461299
- **Lead sponsor:** The Dermatology Institute of Boston
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-17
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06461299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06461299, "Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT06461299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*